CJC-1295 and Sermorelin are both growth hormone-releasing hormone analogs that stimulate the pituitary to produce GH—but their half-lives, dosing schedules, and clinical profiles differ enough to matter when choosing a protocol. Here's what the research shows about each, side by side.
Both peptides activate the same receptor: the GHRH receptor on pituitary somatotroph cells. What separates them is how long they stay active—and how that affects your GH pulse pattern. Neither is FDA-approved for general use in healthy adults, and neither should be approached without provider-issued prescription and clinical oversight.
This comparison covers mechanism, half-life, dosing, evidence base, and the clinical considerations that separate the two.
How Both Peptides Work: GHRH Receptor Activation
Growth hormone-releasing hormone (GHRH) is a 44-amino-acid peptide released by the hypothalamus. It binds to GHRH receptors on pituitary somatotrophs, triggering synthesis and release of growth hormone (GH).
Sermorelin is a truncated analog of native GHRH containing the first 29 amino acids—the minimum sequence needed to activate the receptor. CJC-1295 is also a 30-amino-acid GHRH analog, but with key differences in structure that dramatically change its pharmacokinetics.
Both peptides are compounded, not FDA-approved for the indications typically discussed in wellness and longevity contexts. Both require provider evaluation and a provider-issued prescription. Subject to medical approval by a licensed provider.
CJC-1295 vs Sermorelin: Head-to-Head Comparison
| Feature | Sermorelin | CJC-1295 (No DAC) | CJC-1295 (With DAC) |
|---|---|---|---|
| Structure | GHRH(1-29): first 29 amino acids of native GHRH | Modified GRF(1-29): 4 amino acid substitutions protecting from DPP-IV degradation | Modified GRF(1-29) + Drug Affinity Complex (albumin binding) |
| Half-life | ~10–20 minutes | ~25–30 minutes | ~7–8 days |
| Dosing frequency | Daily (typically bedtime) | Once to twice daily | Once or twice weekly |
| GH release pattern | Pulsatile—closely mimics natural rhythm | More sustained than sermorelin, still pulsatile | Prolonged GH elevation; less pulsatile |
| Typical subcutaneous dose | 200–300 mcg | 100–300 mcg | 1–2 mg |
| Approval status | Not FDA-approved in current compounded form | Not FDA-approved | Not FDA-approved |
| Common combinations | Often stacked with ipamorelin | Often stacked with ipamorelin | Less commonly stacked |
Why Half-Life Differences Matter Clinically
The natural GH secretion pattern is pulsatile: brief, sharp bursts—primarily during sleep—separated by low baseline levels. This pattern matters for downstream signaling, including IGF-1 production in the liver.
Sermorelin's short half-life means it closely mimics this pulsatile rhythm. Each injection triggers a GH pulse that rises and falls over roughly an hour. That's close to what the hypothalamus does naturally.
CJC-1295 without DAC (also called Modified GRF 1-29) extends the active window to about 30 minutes—still pulsatile, but with a slightly more sustained peak. It achieves this by substituting four amino acids at positions prone to enzymatic degradation by DPP-IV (dipeptidyl peptidase-IV).
CJC-1295 with DAC adds a chemical modification that allows the peptide to bind reversibly to albumin in the bloodstream, extending the half-life to approximately 7–8 days. This creates sustained GH elevation between weekly doses—a fundamentally different pharmacodynamic profile than the pulsatile approach.
If you're exploring GH peptide protocols, the CJC-1295 and ipamorelin stack and the sermorelin overview at TelosRX cover the research background for each in more depth.
Sermorelin: What the Research Shows
Sermorelin was originally developed and FDA-approved (as Geref) as a diagnostic agent for GH deficiency. That approval has since lapsed, and the peptide is now available only as a compounded formulation—meaning it is not FDA-approved in its current form.
Preclinical and early human studies document that sermorelin:
- Stimulates pulsatile GH release from pituitary somatotrophs
- Increases IGF-1 levels in subjects with documented GH insufficiency
- Shows a safety profile consistent with native GHRH at therapeutic doses
- Maintains pituitary feedback mechanisms—meaning the pituitary can still downregulate if GH levels rise excessively
That last point is often cited as an advantage over exogenous HGH (human growth hormone). Because sermorelin stimulates natural GH production rather than replacing it, the negative feedback loop from IGF-1 and somatostatin remains intact. This is a theoretical safety consideration, not a proven clinical outcome difference at typical telehealth doses.
The evidence base for sermorelin in healthy adult aging—longevity, body composition, sleep—is substantially thinner than its GH deficiency data. Studies suggest benefit, but high-quality long-term randomized controlled trials in aging adults are limited. Preclinical research and short-term human studies provide the current evidence floor.
CJC-1295: What the Evidence Suggests
CJC-1295 with DAC was the subject of a Phase 2 clinical trial published in 2006 (Teichman et al., J Clin Endocrinol Metab), which documented that a single injection produced sustained GH elevation for 6+ days in healthy adults. IGF-1 levels increased by 28–55% depending on dose, and the effect persisted for weeks after the final injection.
CJC-1295 without DAC (Modified GRF 1-29) has a shorter action profile and is often discussed separately. Some practitioners prefer it specifically because it preserves a more pulsatile GH release pattern than the DAC version.
Neither version of CJC-1295 is FDA-approved. Both are available only as compounded peptides, subject to the same compounding pharmacy regulations and provider oversight requirements as other compounded peptides.
The evidence profile for CJC-1295 in aging, longevity, and body composition is similar to sermorelin: mechanistically plausible, short-term human data suggesting IGF-1 increases, but limited long-term randomized controlled trial data in healthy aging populations.
Which to Consider: Questions for Your Provider
Neither peptide is generically “better.” The right choice depends on your clinical context, goals, and how your provider assesses your GH axis. Some questions worth discussing in your asynchronous evaluation:
- Do you want daily injections or less frequent dosing? Sermorelin and CJC-1295 (No DAC) require daily or twice-daily subcutaneous injections. CJC-1295 with DAC reduces this to once or twice weekly.
- How important is pulsatile GH release to your goals? For sleep-associated GH restoration, pulsatile delivery (sermorelin or No DAC CJC-1295 dosed at bedtime) may align better with natural rhythms.
- Are you combining with a GHRP? Both are commonly combined with ipamorelin, which acts on a different receptor (ghrelin/GHSR) to amplify GH release synergistically.
- What does your IGF-1 level look like? Baseline IGF-1 testing helps contextualize whether you have room for GH axis augmentation and gives a benchmark to measure response.
TelosRX's asynchronous evaluation process captures this kind of clinical history. Start your evaluation at TelosRX, subject to provider approval.
How TelosRX Approaches GH Peptide Protocols
Compounded GH peptides like sermorelin and CJC-1295 are not FDA-approved. Their use requires individualized clinical evaluation—including a review of relevant labs, medical history, and current medications—before a provider-issued prescription is appropriate.
TelosRX operates as an online-first, asynchronous telehealth service. Your intake form is reviewed by a licensed provider who determines whether a GH peptide protocol is clinically appropriate for you. Approval is not guaranteed. If approved, asynchronous check-ins allow ongoing protocol adjustments without requiring synchronous appointments.
Related reading: Sermorelin benefits overview at TelosRX covers the research context in detail, and the TRT evaluation guide explains how hormone protocols generally are structured at TelosRX.
Frequently Asked Questions
Is CJC-1295 or sermorelin FDA-approved?
Neither is currently FDA-approved for use in healthy adults or anti-aging applications. Both are available as compounded peptides prepared under federal compounding regulations. A historical FDA-approved sermorelin product (Geref) has been discontinued. Compounded formulations are not FDA-approved products.
Can I use CJC-1295 and sermorelin together?
Combining them is uncommon because they activate the same GHRH receptor—stacking two GHRH analogs doesn't offer additive benefit the way pairing a GHRH analog with a GHRP (like ipamorelin) does. Your provider determines the most appropriate combination based on your clinical profile and goals.
Which one is better for sleep quality?
Sermorelin and CJC-1295 (No DAC), dosed at bedtime, may support nocturnal GH pulsatility—which is when most natural GH secretion occurs. Whether either improves sleep quality specifically is not established in high-quality clinical trials. Subject to provider evaluation.
Do these peptides affect thyroid or other hormone levels?
GH secretagogues can influence thyroid hormone conversion indirectly (increased GH activity may affect T4-to-T3 conversion). Anyone on thyroid replacement therapy should disclose this during provider evaluation. Your licensed provider reviews drug interactions as part of the intake process.
How long before CJC-1295 or sermorelin shows results?
IGF-1 changes are often measurable within 4–8 weeks. Subjective changes (sleep, energy, body composition) are typically reported over a 3–6 month window in clinical settings. Individual timelines vary based on baseline IGF-1, dosing, and individual GH axis responsiveness.
What's the difference between CJC-1295 with DAC and without DAC?
The Drug Affinity Complex (DAC) allows CJC-1295 to bind to albumin in the blood, extending its half-life from ~30 minutes to ~7–8 days. This shifts dosing from daily to once or twice weekly and changes the GH release pattern from pulsatile to more sustained. Which version is appropriate depends on your clinical goals and provider recommendation.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.